Clinical significance of epidermal growth factor receptor gene mutations on treatment outcome after first-line cytotoxic chemotherapy in Japanese patients with non-small cell lung cancer.

摘要: Introduction The relationship between the EGFR gene mutation status and clinical outcome has not fully been assessed in patients with non-small cell lung cancer (NSCLC) who received cytotoxic agents. aim of this study was to clarify its association. We also examined whether association could be affected by previous gefitinib treatment. Methods Patients advanced or postoperative recurrent NSCLC both chemotherapy monotherapy their treatment course were included study. An determined exons 19 21 direct sequencing. Results Of 194 Japanese relapsed assessable for analysis, 60 through courses. mutations significantly progression-free survival (PFS) first-line regimens multivariate analysis (hazard ratio PFS=0.422; p = 0.0422). In contrast, 28 (47%) after relapse monotherapy, there no differences PFS stratified status. sensitivity was, however, correlated status, retained even second-line setting mutations. Conclusions therefore associated a better regimens. However, observed administered whereas an later settings.